title: [Effect of combined treatment with dopamine receptor agonists and antagonists of aldosterone on the performance of daily blood pressure monitoring in patients with hypertension and concomitant obesity].
abstract: In hypertensive patients with concomitant obesity observed decrease in activity of dopaminergic system in conjunction with increased activity of the renin-angiotensin-aldosterone system. Identified changes point to the advisability of appointing this group of patients the dopamine receptor agonist - bromocriptine-KV and antagonist of aldosterone - veroshpiron. As a result of treatment was an increase in dopamine levels in the urine, a decrease of aldosterone in the blood, normalization of the daily blood pressure monitoring.
authors.forename: V G
authors.initials: VG
authors.lastname: Lyzogub
authors.forename: V O
authors.initials: VO
authors.lastname: Sobol'
authors.forename: O V
authors.initials: OV
authors.lastname: Dolynna
authors.forename: L A
authors.initials: LA
authors.lastname: Kuz'mins'ka
mesh_terms: D000328:Adult; D000368:Aged; D000450:Aldosterone / Q000097:blood; D001794:Blood Pressure / Q000187:drug effects*; D001971:Bromocriptine / Q000627:therapeutic use*; D004298:Dopamine / Q000652:urine; D018491:Dopamine Agonists / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use*; D009765:Obesity / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D011954:Receptors, Dopamine / Q000378:metabolism; D012084:Renin-Angiotensin System / Q000187:drug effects; D013148:Spironolactone / Q000627:therapeutic use*
chemical_list: D018491:Dopamine Agonists; D000451:Mineralocorticoid Receptor Antagonists; D011954:Receptors, Dopamine; D013148:Spironolactone; D001971:Bromocriptine; D000450:Aldosterone; D004298:Dopamine